Please go to the PowerPak homepage
and select a course.
Managing Patients on Immune Checkpoint Inhibitors in the COVID-19 Era: The Importance of Nurse-Pharmacist Collaborations (Webinar Archive)
Jointly provided by Postgraduate Healthcare Education (PHE) and Postgraduate Institute for Medicine (PIM).
This activity is supported by independent educational grants from Bristol-Myers Squibb and Merck & Company.
Lisa M. Holle, PharmD, BCOP, FISOPP
Associate Clinical Professor
UConn School of Pharmacy
Department of Pharmacy Practice
Clinical Pharmacy Specialist
UConn Health Carol and Ray Neag Comprehensive Cancer Center
Andrea Moran, MSN, APRN-BC
Lead Oncology Nurse Practitioner
UConn Health Carol and Ray Neag Comprehensive Cancer Center
Dr. Holle has disclosed that she has served as a consultant for McGraw Hill and has received honoraria from HOPA and PharmCon.
Ms. Moran has disclosed that she has no actual or potential conflict of interest in relation to this program.
The clinical reviewer, Megan May, PharmD, BCOP, has no actual or potential conflict of interest in relation to this program.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Postgraduate Healthcare Education, LLC (PHE) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Credits: 1.5 hour (0.15 ceu)
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
October 5, 2020
October 5, 2021
Type of Activity: Application
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes
This accredited activity has been designed for oncology pharmacists, nurses and nurse practitioners.
How to Earn Credit (Pharmacists)
During the period October 5, 2020 to October 5, 2021 participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
Method of Participation and Request for Credit (nurses)
There are no fees for participating and receiving CME/CE credit for this activity. During the period October 5, 2020 to October 5, 2021 participants, must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course 15611. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.
To provide oncology nurses, nurse practitioners, and pharmacists with advanced and up-to-date knowledge of immune checkpoint inhibitors alone or in combination with other agents for the treatment of cancer, enhance their confidence and competence in identifying and recommending appropriate patient-specific treatments and developing optimal toxicity prevention and management strategies, thus leading to improved patient outcomes during the COVID-19 pandemic and beyond.
Upon completion of this program, participants should be better able to:
- Discuss the current and emerging use of immune checkpoint inhibitors (ICIs) and ICI combination regimens for the treatment of cancer
- Demonstrate interventions to effectively prevent or manage toxicities of ICIs and ICI combination therapies
- Distinguish best practices for managing patients on ICIs during the coronavirus disease 2019 pandemic
- Develop an interprofessional practice model aimed to improve outcomes in patients receiving ICIs
» Slide (PDF)
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine, Bristol-Myers Squibb or Merck & Company. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.